PRLD: Prelude Therapeutics Incorporated Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 43.45
Enterprise Value ($M) 32.32
Book Value ($M) 156.43
Book Value / Share 3.71
Price / Book 0.28
NCAV ($M) 115.60
NCAV / Share 2.74
Price / NCAV 0.38

Profitability (mra)
Return on Invested Capital (ROIC) -0.75
Return on Assets (ROA) -0.51
Return on Equity (ROE) -0.55

Liquidity (mrq)
Quick Ratio 7.04
Current Ratio 7.04

Balance Sheet (mrq) ($M)
Current Assets 156.39
Assets 197.22
Liabilities 40.79
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-13 13G/A Ubs Asset Management Americas Inc 0.00 -100.00
02-12 13G/A Vaddi Krishna 11.10 14.16
02-12 13G/A Flynn James E 9.85 28.25
01-10 13G/A Fmr Llc 0.63 -94.57
12-13 13D/A Baker Bros. Advisors Lp 24.30 0.04

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-05-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-02-15 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-15 106,837 413,023 25.87
2024-11-14 89,644 370,718 24.18
2024-11-13 221,065 431,213 51.27
2024-11-12 100,834 481,633 20.94
2024-11-11 37,441 282,861 13.24

(click for more detail)

Similar Companies
PLRX – Pliant Therapeutics, Inc. PMVP – PMV Pharmaceuticals, Inc.
PRAX – Praxis Precision Medicines, Inc. PRTA – Prothena Corporation plc
PTCT – PTC Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io